Trial Profile
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Tucatinib (Primary)
- Indications Advanced breast cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Seagen
- 21 Feb 2020 Status changed from suspended to completed.
- 30 Mar 2018 Status changed from recruiting to suspended.
- 09 Feb 2018 New trial record